MX2025014195A - Metodos y reactivos para analizar las interfaces entre proteinas - Google Patents
Metodos y reactivos para analizar las interfaces entre proteinasInfo
- Publication number
- MX2025014195A MX2025014195A MX2025014195A MX2025014195A MX2025014195A MX 2025014195 A MX2025014195 A MX 2025014195A MX 2025014195 A MX2025014195 A MX 2025014195A MX 2025014195 A MX2025014195 A MX 2025014195A MX 2025014195 A MX2025014195 A MX 2025014195A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- interfaces
- reagents
- analyzing
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482018P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026014 WO2018187423A1 (en) | 2017-04-05 | 2018-04-04 | Methods and reagents for analyzing protein-protein interfaces |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025014195A true MX2025014195A (es) | 2026-01-07 |
Family
ID=63712343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025014195A MX2025014195A (es) | 2017-04-05 | 2019-10-04 | Metodos y reactivos para analizar las interfaces entre proteinas |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210285955A1 (enExample) |
| EP (1) | EP3607326A4 (enExample) |
| JP (3) | JP2020520988A (enExample) |
| KR (2) | KR20240093922A (enExample) |
| CN (1) | CN110785428A (enExample) |
| AU (2) | AU2018250186B2 (enExample) |
| BR (1) | BR112019020967A2 (enExample) |
| CA (1) | CA3058964A1 (enExample) |
| IL (2) | IL269779B2 (enExample) |
| MX (1) | MX2025014195A (enExample) |
| WO (1) | WO2018187423A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| IL317393A (en) * | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119661684B (zh) * | 2024-10-21 | 2025-11-25 | 山东大学 | 一种高抗炎活性的脂联素突变体及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010374A1 (en) * | 1997-08-26 | 1999-03-04 | Wisconsin Alumni Research Foundation | Cyclosporin a conjugates and uses therefor |
| US7220552B1 (en) * | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| CA2633500A1 (en) * | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
| JP4871960B2 (ja) * | 2006-01-03 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | 優れたシャペロン活性およびフォールディング活性を有するキメラ融合タンパク質 |
| US20090054334A1 (en) * | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
| US9428845B1 (en) * | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| US9260484B2 (en) * | 2011-06-15 | 2016-02-16 | Ohio State Innovation Foundation | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| US10427131B2 (en) * | 2015-03-19 | 2019-10-01 | 3M Innovative Properties Company | Guanidine-functionalized perlite particles, articles containing the particles, and methods of using the particles and articles |
| CA3000822A1 (en) * | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CN105902537A (zh) * | 2016-04-26 | 2016-08-31 | 兰州大学 | 靶向人fkbp51蛋白的先导化合物及其筛选方法与应用 |
| US20200199102A1 (en) * | 2017-04-05 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
-
2018
- 2018-04-04 WO PCT/US2018/026014 patent/WO2018187423A1/en not_active Ceased
- 2018-04-04 CA CA3058964A patent/CA3058964A1/en active Pending
- 2018-04-04 BR BR112019020967-0A patent/BR112019020967A2/pt unknown
- 2018-04-04 KR KR1020247017424A patent/KR20240093922A/ko not_active Ceased
- 2018-04-04 IL IL269779A patent/IL269779B2/en unknown
- 2018-04-04 AU AU2018250186A patent/AU2018250186B2/en active Active
- 2018-04-04 KR KR1020197032295A patent/KR20200003802A/ko not_active Ceased
- 2018-04-04 JP JP2020504095A patent/JP2020520988A/ja active Pending
- 2018-04-04 US US16/500,634 patent/US20210285955A1/en not_active Abandoned
- 2018-04-04 CN CN201880037176.0A patent/CN110785428A/zh active Pending
- 2018-04-04 IL IL324618A patent/IL324618A/en unknown
- 2018-04-04 EP EP18781381.1A patent/EP3607326A4/en active Pending
-
2019
- 2019-10-04 MX MX2025014195A patent/MX2025014195A/es unknown
-
2023
- 2023-06-21 JP JP2023101616A patent/JP7781821B2/ja active Active
-
2024
- 2024-02-22 US US18/584,357 patent/US20240426833A1/en active Pending
- 2024-11-19 AU AU2024266705A patent/AU2024266705A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203641A patent/JP2026041812A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL269779B2 (en) | 2026-04-01 |
| CA3058964A1 (en) | 2018-10-11 |
| CN110785428A (zh) | 2020-02-11 |
| KR20240093922A (ko) | 2024-06-24 |
| AU2024266705A1 (en) | 2024-12-12 |
| IL269779B1 (en) | 2025-12-01 |
| KR20200003802A (ko) | 2020-01-10 |
| JP2020520988A (ja) | 2020-07-16 |
| IL269779A (en) | 2019-11-28 |
| AU2018250186B2 (en) | 2024-12-05 |
| EP3607326A1 (en) | 2020-02-12 |
| WO2018187423A1 (en) | 2018-10-11 |
| JP7781821B2 (ja) | 2025-12-08 |
| IL324618A (en) | 2026-01-01 |
| AU2018250186A1 (en) | 2019-11-14 |
| JP2026041812A (ja) | 2026-03-10 |
| EP3607326A4 (en) | 2020-11-18 |
| US20210285955A1 (en) | 2021-09-16 |
| BR112019020967A2 (pt) | 2020-05-05 |
| US20240426833A1 (en) | 2024-12-26 |
| JP2023134482A (ja) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4242304A3 (en) | Methods and reagents for analyzing protein-protein interfaces | |
| EP4614155A3 (en) | Methods of assaying proteins | |
| EP4567127A3 (en) | Methods for determining a location of a biological analyte in a biological sample | |
| WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
| EP4010456A4 (en) | SYSTEMS AND METHODS FOR SAMPLE PREPARATION, DATA GENERATION AND PROTEIN CORONA ANALYSIS | |
| ZA202001218B (en) | Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry | |
| EP4442706A3 (en) | Canine antibody libraries | |
| MY197854A (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| EP4649966A3 (en) | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging | |
| WO2020239895A3 (en) | Detection of colorectal cancer | |
| WO2021021964A3 (en) | Methods of quantifying frataxin and frataxin fusion proteins | |
| AU2018267843A1 (en) | PD-L1 antibody pharmaceutical composition and use thereof | |
| EP4545521A3 (en) | Compounds that participate in cooperative binding and uses thereof | |
| WO2015006337A3 (en) | Compositions and methods for increasing protein half-life in a serum | |
| EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
| AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| WO2016172551A3 (en) | Methods of identifying bacteria comprising binding polypeptides | |
| ZA202001214B (en) | Systems and methods for performing a real-time glycan assay of a sample | |
| MX2020012713A (es) | Metodos, dispositivos y sistemas para cuantificar biomarcadores. | |
| BR112017008011A2 (pt) | métodos baseados em proximidade para seleção de parceiros de ligação | |
| EP4245374A3 (en) | Pvrl2 and/or pvrig as biomarkers for treatment | |
| WO2022090801A3 (en) | Pvrl2 and/or pvrig as biomarkers for treatment | |
| PH12018502291A1 (en) | Relative potency assay for viral vector encoding isomerohydrolases | |
| WO2020117710A8 (en) | Systems and methods for an integrated consumable for analyte testing, including a premix apparatus | |
| AU2014302811B2 (en) | Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes |